Evaluating the Efficacy of Durvalumab with or without Tremelimumab in Treating Small-Cell Lung Cancer
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on November 27th, 2024
|
Hodgkin’s lymphoma is currently treated with a range of chemotherapy agents, often in various combinations. Among these, brentuximab vedotin has proven effective by targeting tumor cells through binding to CD30, which is widely expressed on their surface. However, this agent is associated with significant toxicity, particularly in pediatric patients. Hodgkin’s lymphoma cells also express high levels of PD-L1, which helps deactivate antitumor immune cells, a process that can be targeted by nivolumab. The National Institutes of Health commissioned a study to compare the effectiveness of brentuximab vedotin and nivolumab when combined with the current standard treatment regimen for Hodgkin’s lymphoma.
The phase 3 clinical trial involved 970 participants aged 12 and older, all diagnosed with stage III or IV Hodgkin’s lymphoma. Participants were randomly assigned to receive either nivolumab or brentuximab vedotin every 28 days. Nivolumab was administered intravenously at a dose of 240 mg for adults and 3 mg per kilogram of body weight for children under 12. Brentuximab vedotin was given at a dose of 1.2 mg per kilogram of body weight. Both groups also received the standard regimen of doxorubicin, vinblastine, and dacarbazine on the 1st and 15th days of the 28-day cycle, at doses of 25 mg, 6 mg, and 375 mg per square meter of body surface area, respectively. After a median follow-up of 12 months, researchers found that adding nivolumab to the standard regimen improved the odds of progression-free survival by 55%, compared to those treated with brentuximab vedotin plus the standard regimen. Nivolumab was associated with fewer adverse effects than brentuximab vedotin, though the latter was linked to a higher incidence of peripheral neuropathy, while nivolumab posed a higher risk of neutropenia.
The phase 3 clinical trial involved 970 participants aged 12 and older, all diagnosed with stage III or IV Hodgkin’s lymphoma. Participants were randomly assigned to receive either nivolumab or brentuximab vedotin every 28 days. Nivolumab was administered intravenously at a dose of 240 mg for adults and 3 mg per kilogram of body weight for children under 12. Brentuximab vedotin was given at a dose of 1.2 mg per kilogram of body weight. Both groups also received the standard regimen of doxorubicin, vinblastine, and dacarbazine on the 1st and 15th days of the 28-day cycle, at doses of 25 mg, 6 mg, and 375 mg per square meter of body surface area, respectively. After a median follow-up of 12 months, researchers found that adding nivolumab to the standard regimen improved the odds of progression-free survival by 55%, compared to those treated with brentuximab vedotin plus the standard regimen. Nivolumab was associated with fewer adverse effects than brentuximab vedotin, though the latter was linked to a higher incidence of peripheral neuropathy, while nivolumab posed a higher risk of neutropenia.